U.S. flag

An official website of the United States government

NM_172250.3(MMAA):c.387C>A (p.Tyr129Ter) AND MMAA-related disorder

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Jan 23, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003401020.5

Allele description [Variation Report for NM_172250.3(MMAA):c.387C>A (p.Tyr129Ter)]

NM_172250.3(MMAA):c.387C>A (p.Tyr129Ter)

Gene:
MMAA:metabolism of cobalamin associated A [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
4q31.21
Genomic location:
Preferred name:
NM_172250.3(MMAA):c.387C>A (p.Tyr129Ter)
HGVS:
  • NC_000004.12:g.145639526C>A
  • NG_007536.2:g.45485C>A
  • NM_172250.3:c.387C>AMANE SELECT
  • NP_758454.1:p.Tyr129Ter
  • LRG_1301t1:c.387C>A
  • LRG_1301:g.45485C>A
  • LRG_1301p1:p.Tyr129Ter
  • NC_000004.11:g.146560678C>A
  • NG_007536.1:g.25229C>A
  • NM_172250.2:c.387C>A
  • p.Y129X
Protein change:
Y129*
Links:
dbSNP: rs796051992
NCBI 1000 Genomes Browser:
rs796051992
Molecular consequence:
  • NM_172250.3:c.387C>A - nonsense - [Sequence Ontology: SO:0001587]

Condition(s)

Name:
MMAA-related disorder
Synonyms:
MMAA-related condition
Identifiers:

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV004119870PreventionGenetics, part of Exact Sciences
criteria provided, single submitter

(ACMG Guidelines, 2015)		Pathogenic
(Jan 23, 2023) 		germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee..

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Details of each submission

From PreventionGenetics, part of Exact Sciences, SCV004119870.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

The MMAA c.387C>A variant is predicted to result in premature protein termination (p.Tyr129*). This variant has been reported, in the homozygous state or heterozygous state with a second causative MMAA variant, in at least two cblA type methylmalonic acidemia patients (MMA) (Lerner-Ellis et al 2004. PubMed ID: 15523652; Table S1 - Manoli et al. 2016. PubMed ID: 26270765; Hörster et al. 2020. PubMed ID: 32754920). Other loss-of-function variants surrounding this region have also been reported to be causative for MMA. This variant is reported in 0.0057% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/4-146560678-C-A). Nonsense variants in MMAA are expected to be pathogenic. Taken together, this variant is interpreted as pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Jun 23, 2024